Published in Blood Weekly, February 22nd, 1999
Severe thrombocytopenia often occurs in patients receiving chemotherapy and in patients with autoimmune disorders. Current treatment strategies for thrombocytopenia may require transfusion of allogeneic platelets, which is associated with serious drawbacks. These include the occurrence of anti-platelet antibodies, which may result in refractoriness to further platelet transfusions, and the potential risk of transfer of bloodborne diseases.
M. Levi and colleagues developed a platelet substitute product (Synthocytes), which is composed of human albumin microcapsules with fibrinogen...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.